2019 Investments Centered around Cell and Gene Therapies
Previous investments set a foundation for later efficiency improvements.
In 2019, cold-chain service providers continued investments in platforms and services designed for gene and cell therapy clinical studies. Marken acquired a logistics firm in Japan, and expanded logistics operations in Philadelphia with a new GMP-compliant plant and liquid nitrogen storage facilities, says president Ariette Van Strien.
Read more on this article by clicking here.
View ResourceOur Expert
Almac Clinical Services
Guided by our extensive clinical supply experience and expertise, Almac Clinical Services is recognised as an innovative, global solution provider within the specialised and complex market of clinical trial supply.
Our integrated and adaptable solutions offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.
Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.